The roles of CC chemokines in response to radiation

Lei Wang¹, Jizong Jiang¹*, Yuan Chen¹, Qingzhu Jia²,³ and Qian Chu¹

Abstract
Radiotherapy is an effective regimen for cancer treatment alone or combined with chemotherapy or immunotherapy. The direct effect of radiotherapy involves radiation-induced DNA damage, and most studies have focused on this area to improve the efficacy of radiotherapy. Recently, the immunomodulatory effect of radiation on the tumour microenvironment has attracted much interest. Dying tumour cells can release multiple immune-related molecules, including tumour-associated antigens, chemokines, and inflammatory mediators. Then, immune cells are attracted to the irradiated site, exerting immunostimulatory or immunosuppressive effects. CC chemokines play pivotal roles in the trafficking process. The CC chemokine family includes 28 members that attract different immune subsets. Upon irradiation, tumour cells or immune cells can release different CC chemokines. Here, we mainly discuss the importance of CCL2, CCL3, CCL5, CCL8, CCL11, CCL20 and CCL22 in radiotherapy. In irradiated normal tissues, released chemokines induce epithelial to mesenchymal transition, thus promoting tissue injury. In the tumour microenvironment, released chemokines recruit cancer-associated cells, such as tumour-infiltrating lymphocytes, myeloid-derived suppressor cells and tumour-associated macrophages, to the tumour niche. Thus, CC chemokines have protumour and antitumour properties. Based on the complex roles of CC chemokines in the response to radiation, it would be promising to target specific chemokines to alleviate radiation-induced injury or promote tumour control.

Keywords: Radiotherapy, Chemokine, CC chemokine, Tumour microenvironment, Radiation-induced injury, Protumour effect, Antitumour effect

Background
RT is administered as a curative or palliative therapy in more than 50% of cancer patients [1]. The most frequent and lethal lesions that occur during radiation include single-strand breaks (SSBs), double-strand breaks (DSBs), DNA-DNA or DNA–protein cross-links, base release and other chemical modifications, and multiple damaged sites in DNA [2, 3]. Most research on improving the efficacy of RT has focused on tumour cells [4]. However, tumour lesions are not purely composed of cancer cells, and multiple components are present with cancer cells. These components include (1) immune cells; (2) fibroblasts and epithelial cells; (3) extracellular matrix proteins; (4) blood and lymphatic vessels; and (5) metabolites, chemokines, and cytokines [5]. RT can influence these components in different manners, thus remodelling the tumour microenvironment. In tumour tissues, radiation could induce local release of inflammatory cytokines, temporarily eradicate local radiation-sensitive immune cell lineages, and promote immune cell trafficking and immune cell activation [6]. Immune cell subtypes, including dendritic cells (DCs) or cytotoxic lymphocytes, promote antitumour immunity. However, suppressive cells could also be attracted by radiation. In these contexts, chemokines play fundamental roles.

Chemokines include different subfamilies according to the domain found at the N-terminus. CC chemokines...
are one of these families and have an N-terminal CC domain [7, 8]. CC chemokines are represented using 28 symbols. The chemokines C–C motif chemokine ligand (CCL)9 and CCL10 are the same chemokine; thus, there are a total of 27 CC chemokines [7, 8]. These chemokines form a complex network that influences the distribution of immune cells in the tumour microenvironment [9].

Although the role of CC chemokines in cancer has been discussed elsewhere, the relationship between radiation and these chemokines has not been described. The aim of this review was to collect information about the involvement of each CC chemokine in radiation (Fig. 1).
CCL2

CCL2, also known as monocyte chemoattractant protein (MCP)-1, can bind to multiple receptors, including CC chemokine receptor (CCR)1 [10], CCR2 [11], CCR4 [12], and CCR5 [13]. CCL2 is also an antagonist of CCR3 [14]. The main function of CCL2 involves the recruitment of monocytes to inflammatory sites [15–17]. In tumours, CCL2 can be secreted by multiple cell types, including tumour cells [18–21], myeloid-derived suppressor cells (MDSCs) [22], mesenchymal stem cells (MSCs) [23], tumour-associated macrophages (TAMs) [19, 24–26], tumour-associated neutrophils (TANs) [27], and cancer-associated fibroblasts (CAFs) [28–30]. It has been reported that RT can induce the expression of CCL2 [31, 32]. In this section, we will discuss the significance of CCL2 in radiation-related events.

CCL2 is involved in the radiation-induced immune response

Promotion of macrophage infiltration

As mentioned previously, one of the most important functions of CCL2 is the recruitment of monocytes. It has been reported that radiation can promote macrophage infiltration in lung cancer. This infiltration may promote tumour progression through the induction of EMT [33] or triggering an immunosuppressive microenvironment [34]. IL-6 was shown to play a positive role in radiation-induced macrophage migration. When IL-6 signalling was blocked, radiation-induced CCL2 upregulation was inhibited. Neutralizing CCL2 significantly reduced the number of migrated macrophages, indicating that CCL2 was downstream of IL-6 signalling and mediated radiation-induced macrophage infiltration [35]. In the radioresistant pancreatic ductal adenocarcinoma (PDAC) model, tumour-derived CCL2 was significantly upregulated, resulting in increased infiltration of inflammatory monocytes and macrophages but not T cells. When CCL2 was blocked by a specific antibody, the recruitment of inflammatory monocytes was impaired, and tumour growth was delayed [36].

Recruitment of T cells

In addition to the effect on monocytes, CCL2 is involved in the recruitment of T cells. In a sarcoma mouse model, 20 Gy radiation upregulated CCL2 expression. This outcome was associated with the activation and increased infiltration of Th1/Tc1 T cells in the tumour microenvironment [38]. In a murine model of head and neck squamous cell carcinoma, mice received 7.5 Gy radiation. Irradiation upregulated CCL2 production, promoting the infiltration of tumour necrosis factor-alpha (TNFα)-producing monocytes and CCR2+ regulatory T cells (Tregs). In this context, monocyte-derived TNFα activated Tregs, inhibiting the effect of RT [39].

The contradictory effects of CCL2 on antitumour immunity may be dependent on the experimental context, especially radiation dose. A higher dose may stimulate a stronger immune response. In most cases, CCL2 attracts immunosuppressive monocytes, which contribute to tumour progression. This finding suggests that inhibiting CCL2 with radiation may promote the efficacy of RT.

CCL2 mediates radioresistance

In a nasopharyngeal carcinoma (NPC) model, CCL2 correlated with radioresistance and metastasis. CCL2 expression was significantly elevated in HONE1-IR cells and recurrent NPC tumours. CCL2 could promote adaptive radioresistance, metastasis, and EMT in NPC cells. Inhibiting CCL2 enhanced the sensitivity of NPC cells to radiation. In clinical cohorts, high CCL2 expression could predict poorer distant metastasis-free survival [40].

CCL2 and radiation-induced toxicity in normal tissue

Although the primary tumour is the direct target of radiation, normal tissues are inevitably irradiated. Radiation-induced injury usually encompasses two phases: an early phase characterized by tissue inflammation and a late phase characterized by tissue fibrosis. Depending on the irradiated site, organs develop radiation-induced injury, including the lung, liver, intestine and neurons. This section will discuss the role of CCL2 in radiation-induced injury.

Radiation-induced lung injury

Increased expression of CCL2 is related to radiation-induced toxicity in normal tissue [41]. In a mouse model of radiation-induced pulmonary injury, both the selective CCL2 inhibitor bindarit (BIN) and knockout of the main CCL2 receptor CCR2 protected against normal lung tissue injury in mice. RT-induced vascular dysfunction and associated adverse effects were
alleviated. RT-induced expression of CCL2 was abrogated by inhibiting CCL2 signalling. Lung fibrosis was delayed by long-term CCL2 signalling inhibition [41]. EMT has been reported to be involved in radiation-induced lung toxicity. Irradiated human pulmonary alveolar epithelial cells (AECs) (HPAEpiC cells) exhibited upregulated CCL2 and CCR4 expression. In vitro treatment with CCL2 induced EMT in HPAEpiC cells. This effect was weakened by the bioactive component of Radix Ophiopogon B, CCR4 knockdown, or U0126 (a MEK/ERK inhibitor) [42]. However, not all radiation doses or modes promoted CCL2 secretion. Release of CCL2 from human umbilical vein endothelial cells (HUVECs) depended on the dose rate, and 4.1 mGy/h was optimal [43]. CCR2, the receptor for CCL2, is a marker of inflammatory monocytes. Mice deficient for CCR2 exhibited no pulmonary fibrosis after being irradiated and showed decreased numbers of infiltrating and interstitial macrophages [44]. Reactive oxygen species (ROS) have been implicated in radiation-induced pulmonary injury and fibrosis [45]. A study revealed that inducible nitric oxide synthase (iNOS) promoted the production of inflammatory cytokines such as CCL2 [46]. This finding suggests that radiation-induced injury was not due to a single factor but to the interaction between multiple factors.

**Radiation-induced brain and liver injury**

CCR2 has been shown to mediate cognitive impairments induced by irradiation. CCR2 knockout (-/-) mice received 10 Gy cranial irradiation. Compared with wild-type mice, CCR2 deficiency prevented hippocampus-dependent spatial learning and memory impairments induced by cranial irradiation. Moreover, CCR2 deficiency normalized the fraction of pyramidal neurons [47]. Irradiation to treat brain tumours could create a chronic neuroinflammatory state resulting in progressive cognitive decline. This effect was associated with the upregulation of CCL2, and inhibiting CCL2 signalling could attenuate this effect [48]. CCL2-deficient mice exhibited attenuated chronic microglial activation, which allowed for the recovery of neurogenesis. In radiation-induced liver damage, multiple chemokines, including CCL2, are released after irradiation. (Myo)fibroblasts in portal vessels may be one of the major sources of these chemokines [49].

Interestingly, not all radiation induces normal tissue injury. Compared with conventional RT (CRT), synchrotron microbeam radiation therapy (MRT) does not induce CCL2 expression in normal tissue [50]. This may explain why synchrotron MRT achieved equivalent tumour control as CRT but showed reduced normal tissue damage. This finding highlights the importance of radiation technology in radiation-induced injury.

**CCL2 as a therapeutic target**

Based on these findings, CCL2 may be a therapeutic target or marker of normal tissue injury during irradiation. Numerous studies have investigated drugs that could prevent the release of radiation-induced inflammatory cytokines. Pravastatin is used to lower cholesterol, and it was found that pravastatin could limit the increase in blood CCL2 induced by radiation [51]. Fibroblast growth factor 2 peptide (FGF-P) is a peptide derived from the receptor-binding domain of fibroblast growth factor 2. In acute gastrointestinal syndrome (AGS) after radiation, FGF-P could reduce several proinflammatory cytokines, including CCL2 [52]. Inhibiting uPA and uPAR abrogated CCL2 expression in meningioma cell lines that were treated with radiation [53]. This outcome was accompanied by reduced ERK activation, nuclear translocation of Rel-A, and NF-κB-DNA binding activity. CCL2 is a marker of late rectal toxicity in prostate cancer patients undergoing RT. In patients with grade 2 late rectal toxicity, CCL2 levels were significantly increased [54]. Evaluating CCL2 levels at an earlier phase and targeting CCL2 may help prevent the development of rectal toxicity.

**CCL3**

CCL3, also known as macrophage inflammatory protein-1α (MIP-1α), was first purified from the supernatant of endotoxin-induced murine macrophages [55]. Multiple cell types can produce CCL3, including immune cell subtypes, fibroblasts, and epithelial cells, as well as platelets, basophils, and eosinophils [56, 57]. CCL3 binds to CCR1, CCR4, and CCR5, exerting various effects on multiple immune cell subtypes. Due to the diverse functions of CCL3, it is involved in diverse biological processes.

**CCL3 is involved in the radiation-induced immune response**

In a hepatocellular carcinoma model, mice treated with MIP-1α and irradiation exhibited significantly enhanced antitumour effects. Immunological markers, including CD8A and CD107A, were also increased [58]. In a phase I clinical trial, patients with breast cancer were treated with intratumoural H$_2$O$_2$ and RT. Blood marker analysis highlighted significant associations between MIP-1α and the tumour response [59]. This finding suggests that blood CCL3 may serve as a predictive marker for treatment response in specific cancer types.
CCL3 and radiation-induced injury
CCL3 was reported to contribute to the development of radiation-induced injury. Both in vitro and in vivo experiments showed that CCL3 was increased by radiation. Mice deficient in CCL3 exhibited reduced inflammation, no significant septal thickening, and small collagen deposition foci in lung tissues after radiation. This effect was mediated by CCR1 but not CCR5. Both CCR1−/− mice and the CCR1 inhibitor BX-471 ameliorated radiation-induced injury. CCR1 has been reported to promote Th2 cell recruitment. In CCR1−/− mice, Th2 cytokines were not increased after irradiation. These results indicated that Th2 cytokines and cells are involved in the development of fibrosis [60]. Samples from radiated human conduit arteries exhibited sustained expression of inflammatory genes, including CCL3, and this radiation-induced CCL3 upregulation was due to NF-κB activation [61]. However, a study showed that in patients with prostate cancer who received three-dimensional conformal radiation therapy, MIP-1α levels were not sensitive to irradiation [62]. Based on these results, CCL3 could be a predictive biomarker for treatment response. This discrepancy in the effects of CCL3 may be attributed to the different responses in specific irradiated sites.

CCL3 as a therapeutic target
Cryptotanshinone (CTS) is a major lipophilic extract from Salvia miltiorrhiza Bunge (Danshen). CTS can attenuate collagen deposition and pulmonary fibrosis in radiation-induced lung injury (RILI) rats by mitigating radiation-induced activation of CCL3 and its receptor CCR1 [63]. The reduced secretion of CCL3 alleviates the radiation-induced inflammatory microenvironment, subsequently attenuating the initiation of fibrosis. Since mitotic cells are highly sensitive to radiation, reducing the number of cells undergoing mitosis may be an ideal approach to protect normal tissues. MIP-1α induces a transient 50% reduction in the number of mitotic cells in small intestinal crypts [64]. BB-10010 is an analogue of MIP-1, and pretreatment with BB-10010 before irradiation significantly increased the number of surviving crypts (10%), which could prevent the side effects associated with RT [65]. This finding may support the use of BB-10010 in patients undergoing abdominal or pelvic treatments. ECI301 is a human MIP-1α variant. Daily administration of 2 µg of ECI301 for 3–5 consecutive days after local irradiation prolonged survival and eradicated tumour growth in CT26 and LLC models. The abscopal effect was observed, and this antitumour effect depended on CD8+ and CD4+ lymphocytes and NK1.1 cells [66].

CCL5
CCL5 (also known as regulated on activation, normally T cell expressed and secreted (RANTES)) belongs to the C–C motif chemokine family. CCL5 binds to CCR5 with high affinity, but it can also bind to CCR1, CCR3 and CCR4 [67]. CCL5 can be found in cancer cells, CAFs, MSCs, MDSCs, TAMs, and anticancer tumour-infiltrating lymphocytes (TILs) [68]. The role of CCL5 in cancer is complicated; it has both protumour and antitumour properties. CCL5 is elevated in multiple tumours and indicates a poor prognosis [69]. However, studies have shown that CCL5 promotes antitumour immunity by recruiting antitumour T cells and DCs to the tumour microenvironment [67]. Thus, CCL5 is a double-edged sword in cancer.

CCL5 promotes tumour progression
Tumour cell-derived CCL5
Macrophages are predominantly found in the tumour microenvironment. Although RT is effective at reducing primary tumours, it may enhance macrophage infiltration to tumour sites, accelerating tumour progression [70, 71]. In oesophageal squamous cell carcinoma, RT enhanced the expression levels of 12-LOX in tumour cells. Subsequently, CCL5 expression was upregulated through the AKT/NF-κB pathway. Elevated CCL5 can recruit macrophages to tumour tissues and promote their polarization to the immunosuppressive M2 subtype, thereby facilitating metastasis [72]. Similarly, radiation promotes macrophage migration in non-small-cell lung cancer models. CCL5 is responsible for this effect, as blocking CCL5 significantly reduces the number of migrated macrophages. Further analysis showed that CCL5 was upregulated by IL-6, and IL-6 inhibition impaired macrophage migration [35].

MSC-derived CCL5
MSCs play important roles in cancer metastasis and are involved in radiation-induced cancer lung metastasis. In the 4T1 breast cancer model, irradiated MSCs promote lung metastasis. The cGAS–STING signalling pathway is activated in irradiated MSCs. Knockdown of cGAS–STING signalling in MSCs abolished their prometastatic effect. Further analysis identified CCL5 as a downstream molecule. cGAS–STING pathway knockdown impaired CCL5 expression. Knockout of CCL5 in MSCs inhibited lung metastasis and CCR5+ macrophage infiltration. This finding highlights the role of the cGAS–STING-CCL5 pathway in metastasis [73].

Based on these results, CCL5 may indicate a worse prognosis in a specific context. A randomized phase 2 trial compared the efficacy of gemcitabine
to capecitabine-based chemoradiotherapy in locally advanced pancreatic cancer. Baseline plasma samples were collected to identify circulating biomarkers. It was found that higher baseline circulating levels of CCL5 indicated worse overall survival [74].

CCL5 promotes antitumour immunity
CD8+ T cell infiltration after RT is pivotal for tumour control. However, in a radiation-resistant mouse model, RT did not induce CD8+ T cell infiltration. CCL5 is involved in the recruitment of CD8+ T cells, which has been confirmed in solid tumours [75]. Studies have shown that CCL5 expression is much higher in parental tumour tissue than in radioresistant tumour tissue [76]. This finding highlights the role of CCL5 in CD8+ T cell infiltration.

Low CD8+ T cell infiltration and high programmed death ligand 1 (PD-L1) expression in pancreatic cancer predicts poor outcomes. Radiation combined with vaccination upregulates the expression of the chemokines CXCL10 and CCL5 in the tumour, along with increased CD8+ T cell infiltration. The use of anti-PD-L1 antibodies further enhanced the efficacy of the combination [77]. AZD6738 is an ATR inhibitor that has been investigated in early phase clinical trials. AZD6738 combined with RT significantly improved the efficacy of radiation. Increased infiltration of CD3+ and NK cells was observed in the tumour. In vitro and in vivo data demonstrated that ATRi plus RT promoted the production of CCL3, CCL5, and CXCL10 in tumour cells [78]. The released chemokines may contribute to the infiltration of antitumour immune cells. These results indicated that the presence of CCL5 promotes antitumour immunity and predicts a better response to treatment.

CCL5 and radiation-induced injury
As mentioned previously, CCL2 contributes to radiation-induced EMT in HPAEpiC cells. CCL5 mediates this process, indicating that CCL5 may contribute to radiation-induced injury [42]. In human irradiated arteries, the inflammasome-associated chemokines CCL2 and CCL5 were elevated. In a mouse model of radiation-induced injury, the same effect was observed. Treatment with the IL-1 receptor antagonist anakinra significantly reduced CCL2 and CCL5 levels in mice. This finding indicated that IL-1 blockade could be a treatment for RT-induced vascular disease [79]. However, CCL5 not only contributes to radiation-induced injury but also protects normal tissue. Haematopoietic regeneration deficiency is a common side effect of RT. In mice with CCR5 deficiency in haematopoietic cells, haematopoietic regeneration was delayed. Further investigation showed that CCL5 was an endothelial cell-secreted haematopoietic growth factor that could bind to CCR5 on haematopoietic cells. CCL5 treatment accelerated haematopoietic regeneration. Mechanistically, CCL5 could promote haematopoietic cell cycling and survival [80]. These two experiments exhibited seemingly contrary results: CCL5 exerted a protective effect on haematopoietic regeneration, but in RT-induced cardiovascular disease, CCL5 promoted injury. This difference may be due to the different effects of CCL5 in different contexts. CCL5 binds to CCR5 on haematopoietic cells but not immune cells, thus promoting haematopoietic regeneration. In irradiated arteries, CCL5 may bind specific receptors on immune cells, thus promoting the development of inflammation.

CCL8
CCL8 is also known as MCP-2. CCL8 can bind to CCR1, CCR2, CCR3, and CCR5 [81]. The main function of CCL8 is to recruit monocytes to inflammatory sites. In addition, CCL8 can attract eosinophils and Tregs [82]. In tumours, CCL8 can promote cancer cell proliferation [83] and migration [84, 85]. The role of CCL8 in radiation-related events is poorly understood. However, CCL8 may participate in lung metastasis. In a Lewis lung cancer model, thorax irradiation with 5 Gy X-ray dramatically increased the number of tumours in the lungs. The administration of nicaraven, a radioprotective agent, significantly reduced the number of tumours in the lungs. Moreover, radiosensitivity was not affected by nicaraven. Further investigation of the underlying mechanism revealed that nicaraven effectively inhibited CCL8 expression and macrophage recruitment [86]. Cranial irradiation can lead to cognitive impairments in patients with brain tumours. Radiation-induced inflammation may be the primary reason for these deficits. It has been reported that CCR2 is critical for macrophage trafficking in the brain. Gene expression analysis revealed radiation-induced gene expression of CCR2 ligands, including CCL8, in the hippocampus. CCR2 deficiency could reduce this induction and prevent hippocampus-dependent spatial learning and memory impairments [47]. This protective effect may be attributed to decreased infiltration of macrophages attracted by CCL8. In human irradiated arteries, CCL8 is dysregulated. This effect may be attributed to NF-kB activation [61]. However, the direct role of CCL8 in radiation-induced cardiovascular disease still needs further investigation.

CCL11
CCL11 is a member of the eotaxin family and is also called eotaxin-1. CCL11 can recruit eosinophils by binding to the receptor CCR3 [7]. CCL11 is a ligand for CCR5 [87]. CCR3 was shown to be expressed in tumour cells,
and activation of this receptor on cancer cells could increase proliferation and migration [88, 89]. Moreover, CCL11 could promote cancer cell apoptosis resistance [90] and angiogenesis [91]. A study showed that severe lung toxicity was associated with lower levels of eotaxin at 24 h after irradiation compared with that in patients who did not develop severe lung toxicity [92]. CCL11 could be a predictive marker of liver toxicity [93]. High-dose irradiation led to skin injury, and this effect was eosinophil-associated. Eosinophil-related Th2 cytokines, including CCL11, were upregulated in irradiated skin and HUVECs. Blocking IL-33 suppressed cytokine secretion in a coculture system of THP-1 cells and irradiated HUVECs, indicating that IL-33 may be a key molecule that regulates this process [94]. Similarly, in the context of radiation-induced brain tissue damage, inflammation-related genes, including CCL11, were strongly induced in endothelial cells [95]. In human dermal fibroblasts, the expression of eotaxin was upregulated by radiation, which may be an important step leading to eosinophilia in patients with radiation exposure [96]. Radiation-induced intestinal fibrosis (RIF) is a serious complication after abdominal RT. Excessive eosinophil accumulation is associated with RIF in both humans and mice. Irradiation increases extracellular adenosine triphosphate, which induces the expression of CCL11 by pericryptal α-SMA+ cells. Eosinophil-deficient mice showed marked amelioration of RIF. Blocking CCR3 by genetic deficiency or neutralizing antibodies suppressed eosinophil accumulation after irradiation in mice, suggesting a role for eosinophils in mice [97].

Other chemokines

CCL7 is involved in the anti-inflammatory response and antitumour immunity [98, 99]. In fibrosis-sensitive C57BL/6 mouse model, total lung RNA was extracted at 26 weeks. CCL7 expression was upregulated, indicating a role in radiation-induced lung fibrosis [100]. CCL22 and CCL17 play pivotal roles in various type-2 T helper cell-dominant diseases. In a rat model of radiation pneumonitis/pulmonary fibrosis, CCL22 and CCL17 were upregulated in irradiated lung tissues. CCL22 and CCL17 were localized primarily to alveolar macrophages, as shown by immunohistochemistry. This finding indicated that macrophages are the primary producers of CCL22 and CCL17. Similarly, bronchoalveolar lavage fluid from patients with idiopathic pulmonary fibrosis exhibited elevated levels of CCL22. The corresponding receptor CCR4 was detected on alveolar lymphocytes and macrophages [101]. Thus, CCL22 and CCL17 are released by alveolar macrophages and may act on CCR4+ type-2 T helper cells and alveolar macrophages to promote pulmonary fibrosis. One of the biological functions of CCL20 is to attract immature DCs and lymphocytes to tissues. Injecting pcDNA3.1/MIP-3α into LLC subcutaneous tumours after radiation significantly delayed tumour growth. The accumulation of DCs was observed in tumour tissues. The local infiltrating lymphocytes after the treatment were predominantly CD8+ T cells [102]. Whole-body irradiation (WBI) depleted DCs in the epidermis and dermis. However, this effect was not due to DC apoptosis. Increased mRNA levels of CCL19/CCL21 and CCR7 in lymph nodes and skin were observed after radiation. CCR7 and its ligands CCL19/CCL21 mediate eDC migration to the draining lymph node. Thus, the radiation-induced depletion of DCs was due to DC migration to the lymph node. In vitro experiments showed that the number of DCs that migrated to CCL19-containing medium increased, indicating that chemokines regulated the migration of DCs [103]. However, a study showed that γ-ray irradiation could significantly inhibit the production of PEG2 and the expression of CCR7 induced by LPS. Eventually, the migration of DCs towards CCL19 is impaired in vitro and in vivo [104]. Low-dose RT (LD-RT) is known to exert an anti-inflammatory effect. In a coculture system of the EC line EA.hy.926 and polymorphonuclear neutrophils (PMNs), irradiation with a low dose between 0.5 and 1 Gy resulted in a significant reduction in CCL20 expression. Moreover, PMN/EA.hy.926 EC adhesion was significantly decreased [105]. In nasopharyngeal carcinoma, CCL22 was significantly increased in patient-derived xenograft tumours or cell lines upon radiation. In serum collected from patients who received RT, this effect was confirmed. Further experiments revealed that CCL22 could recruit CCR4+ CD8+ T cells, which could enhance antitumour immunity [106]. Radiation could induce CCL27 production in the human keratinocyte cell line HaCaT. This effect depended on crosstalk between TNF-α and ROS. CCL27 production promotes skin immune and inflammatory reactions. However, the mechanism of CCL27 still needs investigation [107].

Conclusion

CC chemokines mainly exert chemotactic effects, attracting monocytes, DCs, and T lymphocytes, which are involved in inflammatory reactions and antiviral effects. Radiation stimulates the production of these chemokines (Table 1). In this review, we mainly focused on the chemokines CCL2, CCL3, CCL5, CCL8, CCL11, CCL20, and CCL22. Multiple types of cells can produce CC chemokines, including tumour cells, endothelial cells, fibroblasts, and MSCs. The released chemokines bind to the corresponding receptors in an autocrine or paracrine manner. The most common effects of released chemokines were the recruitment of
immune cells, including lymphocytes, macrophages, neutrophils and eosinophils, to irradiated sites, which could form an inflammatory environment. In normal tissues, this recruitment usually leads to acute and late radiation side effects. Radiation-induced chemokines can be detected in serum and thus could be used as predictive biomarkers. However, the time at which to measure serum levels of specific chemokines may differ in different cancer types. The optimal cut-off values of the predictive chemokines need to be critically evaluated. Several studies have identified relevant factors that inhibit specific chemokines to alleviate radiation-induced injury. This finding indicated that CC chemokines could be promising targets to inhibit the side effects of radiation. However, it should be noted that these strategies may influence the systematic inflammatory response, leading to serious side effects.

In tumour tissues, the infiltration of these immune cells, especially macrophages, can promote metastasis or radioresistance. However, in some cases, anti-cancer effector cells are recruited to facilitate tumour control. Some chemokines, such as CCL2 and CCL5, exert both protumour and antitumour effects. Thus, it is difficult to target these chemokines as a treatment strategy. The protective effects of specific chemokines have been reported, which could exert induce antitumour immunity. To maximize the antitumour effects of chemokines, radiation doses, fractions or techniques should be taken into consideration. The patterns of chemokine release may differ in response to different

| Cell types          | Producer (stimulator)                  | Recipient/signaling type (receptor) | Physiological effects                                      | Reference |
|---------------------|---------------------------------------|------------------------------------|------------------------------------------------------------|-----------|
| CCL2                | Normal cell, Human pulmonary AEC cells| Autocrine (CCR4)                   | Lung fibrosis                                              | [42]      |
|                     | Normal cell, (Myo)fibroblasts          | Neutrophiles                       | Liver damage                                               | [49]      |
|                     | Normal cell, Irradiated brain (not specific) | Microglial                        | CNS injury                                                 | [48]      |
|                     | Cancer cell, A549, H157                | Macrophage                         | Tumor promoting                                            | [35]      |
|                     | Cancer cell, Mouse pancreatic cancer cell lines | Inflammatory monocytes and macrophages | Radoresistance                                             | [36]      |
|                     | Cancer cell, HT1080, MPNST724, SK-LMS1, SW684 | Th1/Tc1 T cells                  | Tumor control                                              | [38]      |
|                     | Cancer cell, Tc1 cells                 | Monocyte and CCR2(+) regulatory T cells | Radoresistance                                             | [39]      |
|                     | Cancer cell, CNE2, HONE1, SUNE2 cells | CCR2(+), MDSC                      | Radoresistance                                             | [37]      |
|                     | Cancer cell, MC38, LLC cells           | Cancer cell                        | Radoresistance, metastasis and epithelial-mesenchymal transition | [40]      |
|                     | CCL3                                 | Normal cell, Irradiated lung tissue (not specific) | CCR1(+), CD4 and CD8 T cells, and macrophages | Radiation-induced lung injury | [60]      |
|                     | Normal cell, Human conduit arteries    | Not specific                       | Cardiovascular disease after irradiation                  | [61]      |
|                     | CCL5                                 | Normal cell, Human pulmonary AEC cells | Autocrine (CCR4)                                | Pulmonary fibrosis | [42]      |
|                     | Normal cell, Endothelial cells         | CCR5(+), hematopoietic cells       | Hematopoietic regeneration                                | [80]      |
|                     | Cancer cell, Eca109, Kyse150 cells    | Macrophages                        | Cellular Metastasis                                        | [72]      |
|                     | Cancer cell, Mesenchymal stem cells   | CCR5(+) macrophages                | Lung Metastasis                                            | [73]      |
|                     | Cancer cell, A549, H157 cells         | Macrophage                         | Tumor promoting                                            | [35]      |
|                     | Cancer cell, B16 cells                | CD8+ T cell                        | Tumor control                                              | [76]      |
|                     | CCL8                                 | Normal cell, Irradiated lung tissues (not specific) | Macrophage                                                | Lung metastasis | [86]      |
|                     | Normal cell, Irradiated hippocampal (not specific) | Not specific | Cognitive impairments                                     | [47]      |
|                     | CCL11                                | Normal cell, Pericryptal alpha-SMA (+) cells | CCR3(+), Eosinophil | Radiation-induced intestinal fibrosis | [97]      |
|                     | Normal cell, Irradiated skin          | Eosinophil                         | Radiation-induced skin injury                              | [94]      |
|                     | Normal cell, Dermal fibroblasts       | Eosinophil                         | Eosinophilia                                               | [96]      |
|                     | Normal cell, Endothelial cells        | Not specific                       | Radiation-induced brain tissue damage                      | [95]      |
|                     | CCL20                                | Cancer cell, LLC cells             | DC, lymphocytes                                           | Tumor control | [102]     |
|                     | CCL22                                | Normal cell, Human NPC cell lines, patient-derived tumor xenograft tumors | CCR4(+), CD8 T cell | Tumor control | [106]     |
|                     | Normal cell, Irradiated lung tissues (not specific) | Alveolar lymphocytes and alveolar macrophages | Radiation pneumonitis/pulmonary fibrosis | [101]     |
doses or fractions. Both preclinical experiments and clinical trials are needed to confirm the optimal doses to boost antitumoural chemokines.

Although the role of chemokines in radiation is complex, investigation of the responses of the chemokines to RT may lead to the development of novel treatments.

**Abbreviations**
cGAS-STING: Cyclic GMP-AMP synthase stimulator of interferon genes; CAF: Cancer-associated fibroblasts; CRT: Conventional radiotherapy; DC: Dendritic cells; DNA: Deoxyribonucleic acid; DSB: Double-strand breaks; EMT: Epithelial-mesenchymal transition; FGF-P: Fibroblast growth factor 2; HUVECs: Human umbilical vein endothelial cells; IFN: Interferon; iNOS: Nitric oxide synthase; MCP-1: Monocyte chemoattractant protein 1; MDSCs: Myeloid-derived suppressor cells; MIF-1α: Macrophage inflammatory protein-1α; MSC: Mesenchymal stem cells; MRT: Synchrotron microbeam radiation therapy; NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B cells; NPC: Nasopharyngeal carcinoma; PDAC: Pancreatic ductal adenocarcinoma; PD-L1: Programmed death ligand 1; TAMS: Tumor-associated macrophages; TAN: Tumor-associated neutrophils; TILs: Tumor-infiltrating lymphocytes; Treg: Regulatory T lymphocytes; RT: Radiotherapy; TNF: Tumor necrosis factor-alpha; RANTES: Regulated on activation, normally T cell expressed and secreted; RIF: Radiation-induced intestinal fibrosis; ROS: Reactive oxygen species.

**Acknowledgements**
Not applicable.

**Author’s contributions**
LW collected published articles and wrote the manuscript. QC put forward the idea of the review. JJ revised the content of the article. YC and QJ edited the manuscript. All authors read and approved the final manuscript.

**Funding**
This work was supported by the following grants: National Natural Science Foundation of China (Grant No. 82072597), Beijing Xisike Clinical Oncology Research Foundation (No. Y-XD2019-214, No. Y-2019Roche-149).

**Availability of data and materials**
Not applicable.

**Declarations**

**Ethics approval and consent to participate**
Not applicable.

**Consent for publication**
Not applicable.

**Competing interests**
The authors declare that they have no competing interests.

**Author details**
1Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan 430030, People’s Republic of China. 2Chongqing Key Laboratory of Immunotherapy, Chongqing, People’s Republic of China. 3Department of Oncology, Xinqiao Hospital, Third Military Medical University, Chongqing, People’s Republic of China.

**References**

1. Rodriguez-Ruiz ME, Vitale I, Harrington KJ, Melero I, Galluzzi L. Immunological impact of cell death signaling driven by radiation on the tumor microenvironment. Nat Immunol. 2020;21(2):120–34.
2. Alizadeh E, Orlando TM, Sanchez L. Biomolecular damage induced by ionizing radiation: the direct and indirect effects of low-energy electrons on DNA. Annu Rev Phys Chem. 2015;66:379–98.
3. Eriksson D, Stigbrand T. Radiation-induced cell death mechanisms. Tumour Biol. 2010;31(4):363–72.
4. Barker HE, Paget JT, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015;15(7):409–25.
5. Portella L, Scala S. Ionizing radiation effects on the tumor microenvironment. Semin Oncol. 2019;46(3):254–60.
6. Jagodinsky JC, Harari PM, Morris ZS. The Promise of Combining Radiation Therapy With Immunotherapy. Int J Radiat Oncol Biol Phys. 2020;108(1):6–16.
7. Hughes CE, Nibbs RJ. A guide to chemokines and their receptors. FEBS J. 2018;285(16):2944–71.
8. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12(2):121–7.
9. Viola A, Sarukhan A, Bronte V, Molon B. The pros and cons of chemokines in tumor immunology. Trends Immunol. 2012;33(10):496–504.
10. Dagooussat M, Suffee N, Hlawaty H, Haddad O, Charni F, Laguillier C, et al. Monocyte chemoattractant protein-1 (MCP-1)/CCL2 secreted by hepatic myofibroblasts promotes migration and invasion of human hepatoma cells. Int J Cancer. 2010;126(5):1095–108.
11. Monteclaro F, Chao I. The amino-terminal domain of CCR2 is both necessary and sufficient for high affinity binding of monocyte chemoattractant protein 1. Receptor activation by a pseudo-tethered ligand. J Biol Chem. 1997;272(37):23186–90.
12. Sun W, Li WJ, Wei FQ, Wong TS, Zhou XL, et al. Blockade of MCP-1/CCL2 signaling-induced recruitment of activated regulatory cells evokes an antitumor immune response in head and neck squamous cell carcinoma. Oncotarget. 2016;7(25):37714–27.
13. Blanpain C, Migeotte I, Lee B, Vakili J, Doranz B, Govaerts C, et al. CCR5 chemokine and chemokine-like domains of CCL2 and CXCL16 in vitro. Biochem Biophys Res Commun. 2014;443(1):1218–25.
14. Proost P, Wuyts A, Van Damme J. Human monocyte chemotactic protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 2004;24(1):38–46.
15. Lu B, Rutledge BJ, Gu L, Fiorillo J, Lukacs NW, Kunkel SL, et al. Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein-1 deficient mice. J Exp Med. 1998;187(4):601–8.
16. Deshmule SN, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 2009;29(6):313–26.
17. Proost P, Wuys A, Van Damme J. Human monocyte chemotactic proteins-2 and -3: structural and functional comparison with MCP-1. J Leukoc Biol. 1996;59(1):67–74.
18. Ohto M, KIzada Y, Tanaka S, Yoshihara M, Yasui W, Mukaida N, et al. Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human esophageal squamous cell carcinomas. Int J Cancer. 2002;102(3):220–4.
19. Koide N, Nishio A, Sato T, Sugiyama A, Miyagawa S. Significance of macrophage chemoattractant protein-1 expression and macrophage infiltration in squamous cell carcinoma of the esophagus. Am J Gastroenterol. 2004;99(9):1667–74.
20. Desai S, Kumar A, Laskar S, Pandey BN. Cytokine profile of conditioned medium from human tumor cell lines after acute and fractionated doses of gamma radiation and its effect on survival of bystander tumor cells. Cytokine. 2013;61(1):33–26.
21. Dutta P, Sarkissyan M, Paico K, Wu Y, Vadgama J. MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasis. Breast Cancer Res Treat. 2018;170(3):477–86.
22. Han E, Lee J, Ryu S, Choi C. Cytokine-conditioned Gr-1+CD11c+ myeloid cells induce angiogenesis through the synergistic action of CCL2 and CXCL16 in vitro. Biochem Biophys Res Commun. 2014;443(1):1218–25.
23. Jia XH, Du Y, Mao D, Wang ZL, He ZZ, Qiu JD, et al. Zoledronic acid prevents the tumor-promoting effects of mesenchymal stem cells via MCP-1-dependent recruitment of macrophages. Oncotarget. 2015;6(28):26018–28.

24. Mohamed M, El-Shanawmy E, Nohal M, Schneider R, Stoebe B, El-Shanawwi M. Cytokines secreted by macrophages isolated from tumor microenvironment of inflammatory breast cancer patients possess chemotactic properties. Int J Biochem Cell Biol. 2014;46:138–47.

25. Chang A, Miska J, Wainwright D, Dey M, Rivetta C, Yu D, et al. CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells. Can Res. 2016;76(19):5671–82.

26. Gabrusiewicz K, Rodriguez B, Wei J, Hashimoto Y, Healy LM, Maiti SN, et al. Globostroma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight. 2016;1(2): e85841.

27. Zhou SL, Zhou ZJ, Hu QZ, Huang WX, Wang Z, Chen EB, et al. Tumor-associated neutrophils recruit macrophages and T-regulatory cells to promote progression of hepatocellular carcinoma and resistance to sorafenib. Gastroenterology. 2016;150(7):1646-1658 e17.

28. Silzle T, Kreutz M, Dobler M, Brockhoff G, Knuechel R, Kunz-Schughart L. Tumor-associated fibroblasts recruit blood monocytes into tumor tissue. Eur J Immunol. 2003;33(5):1311–20.

29. Subramaniam KS, Tham SJ, Mohamed Z, Wook YL, Mat Adenan NA, Abdul Razak NA, et al. Cytokine profile of breast cell lines after different radiation doses. Oncol Biol Phys. 2015;183(4):447–54.

30. Yang X, Lin Y, Shi Y, Li B, Liu Y, Yin W, et al. FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling. Cancer Res. 2016;76(14):4124–35.

31. Bravata V, Miniati L, Forte GI, Giannattasio FP, Russo G, Di Magni FW, et al. Cytokine profile of breast cell lines after different radiation doses. Int J Radiat Biol. 2017;93(11):1217–26.

32. Wang P, Guo F, Han L, Wang X, Li J, Guo Y, et al. X-ray-induced changes in the expression of inflammation-related genes in human peripheral blood. Int J Mol Sci. 2014;15(11):19516–34.

33. Dehai C, Bo P, Qiang T, Lihua S, Fang L, Shi J, et al. Enhanced invasion of lung adenocarcinoma cells after co-culture with THP-1-derived macrophages via the induction of EMT by IL-6. Immunol Lett. 2014;160(1):1–10.

34. Kmetta T, Gillgrass A, Ashkar AA. The influence of macrophages and the tumor microenvironment on natural killer cells. Curr Mol Med. 2013;13(3):68–79.

35. Wang X, Yang X, Tsai Y, Yang L, Chuang KH, Keng PC, et al. IL-6 mediates macrophage infiltration after irradiation up-regulation of CCL2/CCL5 in non-small cell lung cancer. Radiat Res. 2017;187(1):50–9.

36. Kalbasi A, Komar C, Tooker GM, Liu M, Lee JW, Gladney WL, et al. CCL2-dependent recruitment of tregs and monocytes following cranial irradiation. Brain Behav Immun. 2013;30:33–9.

37. Malik IA, Moncorri F, Sheikh N, Naiz K, Khan S, Dudas J, et al. Single-dose gamma-irradiation induces up-regulation of chemokine gene expression and recruitment of granulocytes into the portal area but not into other regions of rat hepatic tissue. Am J Pathol. 2010;176(4):1801–15.

38. Yang Y, Swierczek A, Ihabim M, Paiva F, Cann L, Stevenson AW, et al. Synchrotron microbeam radiotherapy evokes a different early tumor immunomodulatory response to conventional radiotherapy in EMT6 mammary tumors. Radiother Oncol. 2019;133:93–9.

39. Holler V, Board Y, Gaugler MH, Guipaud O, Baudelin C, Sacher A, et al. P vaccinatis limits radiation-induced vascular dysfunction in the skin. J Invest Dermatol. 2009;129(5):1280–91.

40. Zhang L, Sun W, Wang J, Zhang M, Yang S, Tian Y, et al. Mitigation effect of an FGF-2 peptide on acute gastrointestinal syndrome after high-dose irradiation. Radiat Res. 2010;174(4):261–8.

41. Nalla AK, Gorgeni VR, Gupta R, Dinh DH, Rao JS. Suppression of uPA and uPAR blocks radiation-induced MCP-1 mediated recruitment of endothelial cells in meningioma. Cell Signal. 2011;23(8):1299–310.

42. Bedini N, Cicchetti A, Palorini F, Magnani T, Zuco V, Pennati M, et al. Evaluation of mediators associated with the inflammatory response in prostate cancer patients undergoing radiotherapy. Dis Markers. 2018;2018:9128128.

43. Groves AM, Johnston CJ, Williams JP, Finkelstein JN. Role of infiltrating macrophages via the induction of EMT by IL-6. Immunol Lett. 2015;167(2):570–81.

44. Malaviya R, Gow AJ, Francis M, Abramova EV, Laskin JD, Laskin DL. Inducible nitric oxide synthase and surfactant protein D. Toxicol Sci. 2015;167(2):570–81.

45. Wolpe SD, Davatelis G, Sherry B, Beutler B, Hesse DG, Nguyen HT, et al. Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties. J Exp Med. 1998;186(2):570–81.

46. Schaller TH, Bhatia KC, Suryadevara CM, Desai R, Sampson JH. Chemokines as adjuvants for immunotherapy: implications for immune activation with CCL3. Expert Rev Clin Immunol. 2017;13(11):1049–60.

47. Santitomas-Thapopoulos I, Fotiou D, Terpos E. CCL3 Signaling in the tumor microenvironment. Adv Exp Med Biol. 2020;1213:13–21.

48. Jeong KY, Lee EJ, Yang SH, Seong J. Combination of macrophage inflammatory protein 1 alpha with existing therapies to enhance the antitumor effects on murine hepatoma. J Radiat Res. 2015;56(1):37–45.

49. Nimalasena S, Gottard S, Anbalagan S, Allen S, Sinnett V, Mohammed K, et al. Intratumoral hydrogen peroxide with radiation therapy in locally advanced breast cancer: results from a phase 1 clinical trial. Int J Radiat Oncol Biol Phys. 2020;108(4):1019–29.

50. Yang X, Walton W, Cook DN, Hua X, Tilley S, Haskell CA, et al. Intratumoral hydrogen peroxide with radiation therapy in locally advanced breast cancer: results from a phase 1 clinical trial. Int J Radiat Oncol Biol Phys. 2020;108(4):1019–29.

51. Wolpe SD, Davatelis G, Sherry B, Beutler B, Hesse DG, Nguyen HT, et al. Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties. J Exp Med. 1998;186(2):570–81.

52. Santitomas-Thapopoulos I, Fotiou D, Terpos E. CCL3 Signaling in the tumor microenvironment. Adv Exp Med Biol. 2020;1213:13–21.

53. Jeong KY, Lee EJ, Yang SH, Seong J. Combination of macrophage inflammatory protein 1 alpha with existing therapies to enhance the antitumor effects on murine hepatoma. J Radiat Res. 2015;56(1):37–45.

54. Nimalasena S, Gottard S, Anbalagan S, Allen S, Sinnett V, Mohammed K, et al. Intratumoral hydrogen peroxide with radiation therapy in locally advanced breast cancer: results from a phase 1 clinical trial. Int J Radiat Oncol Biol Phys. 2020;108(4):1019–29.

55. Yang X, Walton W, Cook DN, Hua X, Tilley S, Haskell CA, et al. Chemokine CCL3, and its receptor,CCR1, mediate thoracic radiation-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2011;45(1):127–35.

56. Halle M, Gabrielsen A, Paulson-Berne G, Gahm C, Agardh HE, Fornebo F, et al. Sustained inflammation due to nuclear factor-kappa B activation in irradiated human arteries. J Am Coll Cardiol. 2010;55(12):1227–36.

57. Lopes CO, Callera F. Three-dimensional conformal radiotherapy in prostate cancer patients: rise in interleukin 6 (IL-6) but not IL-2, IL-4, IL-5, tumor necrosis factor-alpha, MIP-1-alpha, and LIF levels. Int J Radiat Oncol Biol Phys. 2012;82(4):1385–8.
63. Jiang Y, You F, Zhu J, Zheng C, Yan R, Zeng J. Cryptopothasinone amelo-
riates radiation-induced lung injury in rats. Evid Based Complement Alternat Med. 2019;2019:1908416.
64. Arango D, Ettarh RR, Brennan PC. BB-10010, an analogue of macro-
phage inflammatory protein-1 alpha, reduces proliferation in murine small intestine crypts. Scand J Gastroenterol. 1999;34(1):68–72.
65. Arango D, Ettarh RR, Holden G, Moriarty M, Brennan PC. BB-10010, an analog of macrophage inflammatory protein-1 alpha, protects murine small intestine against radiation. Dig Dis Sci. 2001;46(12):2688–14.
66. Shiashi K, Ishiwata Y, Nakagawa K, Yokoshi T, Takui C, Akuta T, et al. Enhancement of antitumor radiation efficacy and consistent induction of the abscess effect in mice by EC301, an active variant of macrophage inflammatory protein-1 alpha. Clin Cancer Res. 2008;14(10):1159–66.
67. Aldinucci D, Borgehe C, Casagrande N. The CCL5/CCR5 Axis in Cancer Progression. Cancers (Basel). 2020;12(7):1765.
68. Korbecki J, Grochans S, Gutowska I, Barczak K, Baranowska-Bosiacka I. CC
chemokines in a tumor: a review of pro-cancer and anti-cancer properties of receptors CCR5, CCR6, CCR7, CCR9, and CCR10 Ligands. Int J Mol Sci. 2020;21(20):7619.
69. Jiao X, Nawab O, Patel T, Kossenkov AV, Halama N, Jaeger D, et al. Recent
advances targeting CCR5 for cancer and its role in immuno-oncology. Cancer Res. 2019;79(19):4801–7.
70. Timaner M, Bli R, Kaidar-Person O, Rachman-Tzemah C, Alishekevitz D, Okubo M, Kioi M, Nakashima H, Sugiura K, Mitsudo K, Aoki I, et al. M2-polar-
sis via THP-1-derived macrophages. Onco Targets Ther. 2020;13:7719–33.
71. Mi S, Qu Y, Chen X, Wen Z, Chen P, Cheng Y. Radiotherapy increases 12-LOX
isoforms, and enhances the metastatic potential of colorectal cancer cells. Cancer Lett. 2020;479:53–62.
72. Zheng Z, Jia S, Shao C, Shi Y. Irradiation induces cancer lung metastasis
via activation of the CCR3-ERK pathway and upregulation of MMP-3 expression. Oncol Rep. 2014;31(5):2049–54.
73. Miyagaki T, Sugaya M, Murakami T, Asano Y, Tada Y, Kadono T, et al. CCL11-
CCR3 interactions promote survival of anaplastic large cell lymphoma cells via ERK1/2 activation. Cancer Res. 2011;71(16):2056–65.
74. Park J, Kang YW, Choi BY, Yang YC, Cho BP, Cho WG. CCL11 promotes angiogenic
activity by activating the P38/JAK2 pathway in HUVECs. J Recept Signal Transduct Res. 2017;37(4):416–21.
75. Siva S, MacManus M, Kron T, Best N, Smith J, Lobacchuvsky P, et al. A pattern of early radiation-induced inflammatory cytokine expression is associated with lung toxicity in patients with non-small cell lung cancer. PLoS ONE. 2014;9(10):e109560.
76. Kuno KC, Deviashia T, Sun Y, Schpper ML, Kamak D, Davis MA, et al. Serum levels of hepatocyte growth factor and CD40 ligand predict radiation-
induced liver injury. Transl Oncol. 2019;12(7):889–94.
77. Lee EJ, Kim JW, Yoo H, Kwak W, Choi WH, Cho S, et al. Single high-dose irradiation aggravates eosinophil-mediated fibrosis through IL-33 secreted from impaired vessels in the skin compared to fractionated irradiation. Biochem Biophys Res Commun. 2015;464(1):20–6.
78. Bostrom M, Kalm M, Eriksson Y, Bull C, Stahlberg A, Bjork-Eriksson T, et al. A
mechanism of radioresistance. Sci Rep. 2018;8(1):11934.
79. Christersdottir T, Pirault J, Gistera A, Bergman O, Gallina AL, Baumgartner R, Piryani SO, Kam AYF, Vu UT, Chao NJ, Doan PL. CCR5 Signaling promotes
regulatory T cell engraftment and immune attack in solid tumors. Cancer Cell. 2016;5(6): e1150398.
80. Barbai T, Fejos Z, Puskas LG, Timar J, Raso E. The importance of microenviron-
ment: the role of CCL8 in metastasis formation of melanoma. Oncotarget. 2015;6(30):29111–28.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.